Immunotherapy may be an option for treating some advanced triple negative breast cancers, also called TNBC. TNBC is estrogen-receptor (ER), progesterone-receptor (PR) and human epidermal growth factor receptor-2 (HER2) negative, and is a form of breast cancer that has not responded to drug treatment in the past.
The first immunotherapy treatment approved targets PD-L1 positive, unresectable locally advanced or metastatic TNBC in combination with chemotherapy.
The other is a type of monoclonal antibody (mAb) known as a conjugated mAb. It combines two types of drugs: an antibody and a chemotherapy. The antibody allows the drug to target specific receptors on a cancer cell and then delivers the chemotherapy directly to it. It is approved for patients with metastatic TNBC who have received at least two prior therapies.